YL205 / MediLink - LARVOL DELTA

YL205-CN-101-01: A Clinical Study of YL205 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=252 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

YL205-CN-101-01: A Clinical Study of YL205 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=252 | Not yet recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors (AACR 2024) - "The highly stable nature of TMALIN linker, together with the high potency of the payload, likely mitigates the potential liability of this normal tissue expression. Based on these results, it demonstrates that YL205's advanced ADC design results in an increased therapeutic margin, and YL205 may help address unmet medical need in patients with NaPi2b-expressing tumors."

Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • SLC34A2